Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Nras Q61R/+ and Kras −/− cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors

Zhi Wen, Grant Yun, Alexander Hebert, Guangyao Kong, Erik A. Ranheim, Remington Finn, Adhithi Rajagoplan, Shuyi Li, Yun Zhou, Mei Yu, Alisa Damnernsawad, Jeroen P. Roose, Joshua J. Coon, Renren Wen, Demin Wang, Jing Zhang

Blood (2021) 137 (23): 3259–3271.

https://doi.org/10.1182/blood.2020009082

Published: 2021

Includes: Supplemental data

Journal Articles

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Blood (2021) 137 (15): 2103–2113.

https://doi.org/10.1182/blood.2020007488

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia

Jacob J. Junco, PhD, Vincent Ulysses Gant, PhD, Maci S. Terrell, BS, Matthew Benjamin Miller, MD, Chun Shik Park, PhD, Taylor J Chen, BS, H. Daniel Lacorazza, PhD, Margaret Goodell, PhD, Rachel E. Rau, MD, Karen R. Rabin, MD PhD

Blood (2019) 134 (Supplement_1): 3792.

https://doi.org/10.1182/blood-2019-126858

Published: 2019

Journal Articles

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Tengteng Yu, MD PhD, Liang Lin, PhD, Kenneth Wen, Lijie Xing, MD, Jiye Liu, PhD, Shih-Feng Cho, MD PhD, Phillip Hsieh, Ola Rizq, MD PhD, Yuyin Li, PhD, Liang Yu, Xiang Wu, Eugenio Morelli, MD, Yan Xu, MD, Gang An, MD, Nikhil C. Munshi, MD, Lugui Qiu, MD PhD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 4371.

https://doi.org/10.1182/blood-2019-127454

Published: 2019

Journal Articles

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Bing Li, MD, Jinqin Liu, Tiejun Qin, Zefeng Xu, MD, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2019) 134 (Supplement_1): 2979.

https://doi.org/10.1182/blood-2019-126346

Published: 2019

Journal Articles

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3104.

https://doi.org/10.1182/blood-2019-124391

Published: 2019

Journal Articles

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Blood (2019) 134 (Supplement_1): 509.

https://doi.org/10.1182/blood-2019-128049

Published: 2019

Journal Articles

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

Manja Meggendorfer, PhD, Wencke Walter, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4663.

https://doi.org/10.1182/blood-2019-126449

Published: 2019

Journal Articles

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

Xiaoli Wang, MD PhD, Raajit K. Rampal, MD PhD, Cing Siang Hu, Noushin Farnoud, PhD, Christopher Famulare, MS, Minal A Patel, MPH, Erin McGovern, BA, Ronald Hoffman, MD

Blood (2019) 134 (Supplement_1): 1677.

https://doi.org/10.1182/blood-2019-128836

Published: 2019

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Blood (2019) 134 (Supplement_1): 2091.

https://doi.org/10.1182/blood-2019-128066

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Vijay Negi, PhD, Liat Goldberg, PhD, Yang Jo Chung, PhD, Masahiro Onozawa, MD, Peter D. Aplan, MD

Blood (2019) 134 (Supplement_1): 1346.

https://doi.org/10.1182/blood-2019-128675

Published: 2019

Journal Articles

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Ya-Wei Qiang, MD PhD, Shiqiao Ye, PhD BSc, MSc, Yu Chen, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Brian A Walker, PhD, Frits van Rhee, MD PhD

Blood (2019) 134 (Supplement_1): 4383.

https://doi.org/10.1182/blood-2019-130493

Published: 2019

Journal Articles

Role of Genetic Evolution and Germline Mutations in SAMD9 and SAMD9L Genes

Jason R Schwartz, MD PhD, Marcin W. Wlodarski, MD PhD, Jeffery M. Klco, MD PhD

Blood (2019) 134 (Supplement_1): SCI-33.

https://doi.org/10.1182/blood-2019-121042

Published: 2019

Journal Articles

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Christopher J. Walker, PhD, Ann-Kathrin Eisfeld, MD, Hatice G Ozer, PhD, Jessica Kohlschmidt, PhD, Deedra Nicolet, Krzysztof Mrózek, MD PhD, Dimitrios Papaioannou, MD, Luke K Genutis, BS, Bayard L Powell, MD, Geoffrey L. Uy, MD, Jonathan E. Kolitz, MD, Andrew J. Carroll, PhD, Richard Stone, MD, Ramiro Garzon, MD, John C. Byrd, MD, Albert de la Chapelle, MD PhD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 1247.

https://doi.org/10.1182/blood-2019-127478

Published: 2019

Journal Articles

Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

Blood (2019) 134 (1): 9–21.

https://doi.org/10.1182/blood-2018-11-887141

Published: 2019

Includes: Supplemental data

Journal Articles

Unique dependence on Sos1 in Kras G12D -induced leukemogenesis

Xiaona You, Guangyao Kong, Erik A. Ranheim, David Yang, Yun Zhou, Jing Zhang

Blood (2018) 132 (24): 2575–2579.

https://doi.org/10.1182/blood-2018-09-874107

Published: 2018

Includes: Supplemental data

Journal Articles

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Blood (2018) 132 (Supplement 1): 441.

https://doi.org/10.1182/blood-2018-99-116383

Published: 2018

Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 406.

https://doi.org/10.1182/blood-2018-99-117577

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Nras Q61R/+ and Kras −/− cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

A Novel Short Latency, High Penetrance Model of KRAS Mutation-Driven T-Cell Acute Lymphoblastic Leukemia

Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma

The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

The Genetic Architecture of Myeloproliferative Neoplasms-Blast Phase (MPN-BP) Stem Cells

A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 Thymocytes

Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma

Role of Genetic Evolution and Germline Mutations in SAMD9 and SAMD9L Genes

Distinct Gene Expression Profiles and Mutations Associate with Outcome in Younger Adults with De Novo Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) (Alliance)

Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes

Unique dependence on Sos1 in Kras G12D -induced leukemogenesis

Comprehensive Genomic Analysis of IDH Inhibitor-Treated AML Samples Delineates Molecular Mechanisms of Differentiation and Heterogeneous Patterns of Acquired Resistance

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Email alerts

ASH Publications

American Society of Hematology